Journal
CANCER INVESTIGATION
Volume 26, Issue 3, Pages 269-277Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07357900701708393
Keywords
anaplastic; astrocytoma; oligoastrocytoma; oligodendroglioma; temozolomide
Categories
Ask authors/readers for more resources
Dose-dense temozolomide schedules deplete O-6-methylguanine methyltransferase and may overcome chemoresistance. This multicenter cohort study enrolled 19 patients (15 anaplastic astrocytoma, 4 anaplastic oligoastrocytoma) who received temozolomide (100 mg/m(2)/day for 21 consecutive days every 28-day cycle) at first recurrence, either until disease progression or 12 cycles. Six-month progression-free survival was 56%, comparing favorably with historic controls treated with the standard 5-day temozolomide schedule. Median survival was 12.9 months (95% CI: 3.7, 22 months). Among 15 evaluable patients, 2 had a complete or partial response, and 10 had stable disease. Grade 3 and 4 lymphopenia occurred in 53% and 47% of patients, respectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available